Changeflow GovPing Healthcare FDA Completeness Assessment Correspondence
Routine Notice Added Final

FDA Completeness Assessment Correspondence

Favicon for www.regulations.gov Regs.gov: Food and Drug Administration
Published March 23rd, 2026
Detected March 24th, 2026
Email

Summary

The FDA has posted Completeness Assessment Correspondence related to drug applications. This notice provides information from the Center for Drug Evaluation and Research (CDER) regarding the completeness of submitted applications.

View original document View source feed page

What changed

The FDA has made available Completeness Assessment Correspondence authored by CDER, dated March 23, 2026. This document is associated with the FDA-2026-P-2258-0007 docket and indicates a new piece of information has been added regarding the assessment of drug application completeness.

Compliance officers in the pharmaceutical sector should review this correspondence to understand any potential implications for drug application submissions and review processes. While this appears to be an informational notice, it may contain details relevant to the completeness criteria applied by the FDA. No immediate compliance actions are indicated, but awareness of this communication is advised.

Source document (simplified)

Content

There are no documents available to view or download

Attachments 1

Completeness Assessment Correspondence

More Information
- Author(s) CDER
Download

Related changes

Favicon for www.regulations.gov FDA Complaint Received
Routine Mar 24, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.regulations.gov FDA Complaint Document
Routine Mar 24, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.regulations.gov FDA Complaint Document
Routine Mar 24, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.courtlistener.com Estate of Troy Michael Shafer v. Daryl T Parker Md - Medical Malpractice Appeal
Priority review Mar 24, 2026 • Michigan Court of Appeals • Courts & Legal
Favicon for www.courtlistener.com Joseph Omar Sabir v. NaphCare Inc - Motion to Dismiss Medical Malpractice Claims
Priority review Mar 24, 2026 • EDWA Opinions • Courts & Legal
Favicon for www.gibraltar.gov.gi Gibraltar Introduces 24/7 British Sign Language Interpretation Service
Priority review Mar 24, 2026 • Gibraltar Government Press Releases • Government & Legislation

Source

Favicon for www.regulations.gov
Regs.gov: Food and Drug Administration regulations.gov/search?agencyIds=FDA&sortBy=postedDate&sortDirection=desc
Healthcare
Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
FDA
Published
March 23rd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2026-P-2258-0007
Docket
FDA-2026-P-2258-0007

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Application Submission
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Approval Process

Browse Categories

Agriculture & Food Safety 61 Banking & Finance 236 Consumer Protection 41 Courts & Legal 324 Data Privacy & Cybersecurity 64 Defense & National Security 48 Education 20 Energy 104 Environment 83 Government & Legislation 261 Healthcare 131 Housing 16 Immigration 9 Insurance 56 Labor & Employment 111 Legal & Courts 1 Pharma & Drug Safety 99 Securities & Markets 80 Tax 64 Telecom & Technology 47 Trade & Sanctions 124 Transportation 56

Get Healthcare alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.